TP53 Outperforms Other Androgen Receptor Biomarkers to Predict Outcomes With Abiraterone or Enzalutamide in mCRPC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
TP53 Outperforms Other Androgen Receptor Biomarkers to Predict Abiraterone or Enzalutamide Outcome in Metastatic Castration-Resistant Prostate Cancer
Clin. Cancer Res 2019 Mar 15;25(6)1766-1773, B De Laere, S Oeyen, M Mayrhofer, T Whitington, PJ van Dam, P Van Oyen, C Ghysel, J Ampe, P Ost, W Demey, L Hoekx, D Schrijvers, B Brouwers, W Lybaert, EG Everaert, D De Maeseneer, M Strijbos, A Bols, K Fransis, N Beije, IE de Kruijff, V van Dam, A Brouwer, D Goossens, L Heyrman, GG Van den Eynden, A Rutten, J Del Favero, M Rantalainen, P Rajan, S Sleijfer, A Ullén, J Yachnin, H Grönberg, SJ Van Laere, J Lindberg, LY DirixFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.